×
To start your customized experience click the start button
Customize ?  
Start
Cancer Types
Quick Links
Award Programs
About Us
Careers
Contact Us
Newsroom
Privacy Policy
Terms & Conditions
 
Twitter
Face Book
YouTube
Instagram
 
 
Cure Media Group, LLC.
2 Clarke Drive
Suite 100
Cranbury, NJ 08512
P: 800-210-2873

Copyright © 2019
CURE Media Group.
All rights reserved.
Cure Media Group, LLC. All Rights Reserved.
CURE does not provide medical, diagnostic, or treatment advice.

Lung Cancer

GO2Foundation for Lung Cancer
Merger combines more than 30 years of patient-centered expertise to "Empower Everyone, Ignore No One."
 
GO2Foundation for Lung Cancer
Merger combines more than 30 years of patient-centered expertise to "Empower Everyone, Ignore No One."
Katie Kosko
A model that calculates the probability of cancer may help to rule out a lung cancer diagnosis following screening preventions – which would substantially reduce false positives.
Kristie L. Kahl
Patients with previously treated, advanced NSCLC who received Opdivo therapy experienced a survival benefit over many years, according to a pooled analysis of four studies.
Katie Kosko
Liquid biopsies may be less invasive and faster in determining the genetics of a tumor — and with high accuracy — among those diagnosed with non-small cell lung cancer.
Melba Fujiura
Going through a cancer diagnosis and treatment is so difficult. Thanks to my care team suggesting proton therapy, I never felt like my life became consumed by my lung cancer diagnosis.
Alexandra Guadagno
Immune checkpoint inhibitors were generally well tolerated and may be a viable treatment option for patients with HIV infection and advanced-stage cancer.
Gina Columbus
The Food and Drug Administration (FDA) has granted an approval to the combination of Tecentriq (atezolizumab) with carboplatin and etoposide for the frontline treatment of patients with extensive-stage small cell lung cancer (ES-SCLC).
Kristie L. Kahl
A cancer gene panel using blood may be a cost-effective way of testing the quantity of mutations found in tumors of patients with non-small cell lung cancer.
Kristie L. Kahl
A liquid biopsy test detected all of the guideline-recommended biomarkers in newly diagnosed patients with metastatic non-small cell lung cancer at a similar rate but faster than tissue genotyping.
×
×

Sign In

Not a member? Sign up now!
Continue without login
Continue
×

Sign Up

Patient Caregiver Advocate Other